Fig. 5. Effect of combining the BCL-X_L -targeting PROTAC, DT2216, with encorafenib in BRAF^V600E CRC cells.

A Western blot analysis of BCL-X_L expression following treatment of BRAF^V600E CRC cells with DT2216 (10, 100 and 1000 nM) for 24 h. β-tubulin was used as a loading control. B BRAF^V600E CRC cells were treated with encorafenib (100 nM) and DT2216 (10, 100 or 1000 nM) alone and in combination for 72 h and apoptosis determined by PI staining and FACS analysis. Values shown are mean ± SEM from 3 independent experiments, except for LIM2405 (values shown are mean ± SEM from 2 independent experiments). Differences were compared using one-way ANOVA with Tukey’s multiple comparison testing; ns (not significant), *(p ≤ 0.05), **(p ≤ 0.01), ***(p ≤ 0.001), and ****(p ≤ 0.0001).